|
|
Article: Thermo Fisher Scientific Launches New Biomarker Test in Europe to Rapidly Diagnose Heart Attack.
- Article from:
- Heart Disease Weekly
- Article date:
- November 15, 2009
CopyrightCOPYRIGHT 2009 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, announced the availability in Europe of its new Copeptin assay, which helps medical personnel quickly and accurately diagnose acute myocardial infarction (AMI), commonly known as a heart attack. Copeptin, developed by recently acquired B.R.A.H.M.S. AG, is a patented biomarker for AMI and is detectible using a simple blood test that, in combination with a Troponin biomarker test, permits doctors to rule out or confirm the onset of a heart attack within minutes. Currently, physicians rely on an electrocardiogram in combination with Troponin which, in most patients with chest pain, cannot indicate ...